Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Yash Gandhi¹, Mehmooda Shaikh ², Blisse Vakkalagadda ¹, Grigor Abelian ¹, Neelanjana Ray ¹, Robert Wong ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…
Abstract Number: 2849 • 2019 ACR/ARP Annual Meeting
Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR
Joanna Kedra¹, David Hajage ², Alexandre Lafourcade ², Bernard Combe ³, Maxime Dougados ⁴ and Bruno Fautrel ⁵, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴Cochin Hospital, Paris, France, ⁵Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: In early arthritis, identification of patients at risk of developing joint damage is an important issue. In rheumatoid arthritis (RA), the rate of progression…
Abstract Number: 4 • 2019 ACR/ARP Annual Meeting
AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Lisa Ehlers¹, Aditi Kuppe ¹, Cindy Strehl ¹, Marieluise Kirchner ², Frank Buttgereit ³ and Timo Gaber ¹, ¹Charite University Hospital Berlin, Berlin, Germany, ²Max Delbrück Center for Molecular Medicine, BIH Core Facility Proteomics, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Adenosine and its nucleotides represent crucial immunomodulators in the extracellular environment. ATP and ADP are released from stressed cells in states of inflammation, whereas…
Abstract Number: 57 • 2019 ACR/ARP Annual Meeting
Endothelial Progenitor Cells in the Pathophysiology of Interstitial Lung Disease Associated with Rheumatoid Arthritis
Veronica Pulito-Cueto¹, Sara Remuzgo-Martínez ¹, Fernanda Genre ¹, Leticia Lera-Gomez ¹, Veronica Mijares ¹, Pilar Alonso Lecue ², Victor Manuel Mora Cuesta ², David Iturbe ³, Sonia M. Fernández Rozas ², Ricardo Blanco ⁴, Alfonso Corrales ¹, Jose Manuel Cifrian Martínez ², Raquel López-Mejías ¹ and Miguel A Gonzalez-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the most significant comorbidities that contributes to the increased mortality observed in patients with rheumatoid arthritis (RA)…
Abstract Number: 186 • 2019 ACR/ARP Annual Meeting
Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study
Julia Ford¹, Xinyi Liu ¹, Su H. Chu ², Bing Lu ¹, Michael Cho ¹, Edwin Silverman ¹, Karen Costenbader ¹, Carlos Camargo ³ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: While RA patients are known to have excess respiratory morbidity and mortality, less is known about the role of chronic respiratory diseases in the…
Abstract Number: 276 • 2019 ACR/ARP Annual Meeting
Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis
Sayaka Furukawa¹, Sho Fukui ¹, Sakura Tamaki ², Tomoko Nakasone ³ and Masato Okada ⁴, ¹St.Luke's International Hospital, Chuo-ku, Tokyo, Japan, ²St. Luke's International Hospital, Chuo-ku, Japan, ³St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁴St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Biologics are widely used as treatment for rheumatoid arthritis (RA), and pre-administration screening of active infection is imperative for the safety use. There is…
Abstract Number: 446 • 2019 ACR/ARP Annual Meeting
High MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) Scores in RA Patients Who Have Depression According to a Screening Questionnaire
Rosa Morlà¹, Mariam Riad ², Raul Castellanos-Moreira ³, Virginia Ruiz-Esquide ⁴, Raimon Sanmarti ⁵, Jose Gomez-Puerta ⁶, Theodore Pincus ² and Isabel Castrejon ², ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁴Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Servei de Rheumatologia, Hospital Clinic Universtari, Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Depression in rheumatoid arthritis (RA) patients may be pre-existent, amplified, or may develop after the onset of RA1. The Patient Health Questionnaire (PHQ9) is…
Abstract Number: 472 • 2019 ACR/ARP Annual Meeting
Sleep Quality in Women with Rheumatoid Arthritis Is Associated with Disease Activity and Depressive Symptoms
Deborah Da Costa¹, Teresa Szlachetka ² and Diane Lacaille ³, ¹McGill University, Montreal, QC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Sleep disturbances, including difficulty initiating sleep, maintaining sleep, and/or early morningawakenings are prevalent in persons with rheumatoid arthritis (RA) and can significantly impact quality…
Abstract Number: 516 • 2019 ACR/ARP Annual Meeting
Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib
Michael Weinblatt¹, Eduardo Mysler ², Andrew Östör ³, Aaron Broadwell ⁴, Slawomir Jeka ⁵, Kendall Dunlap ⁶, Jessica Suboticki ⁶, Jose Jeffrey Enejosa ⁶, Barbara Hendrickson ⁶, Sheng Zhong ⁶, Katya Cherny ⁶ and Grace Wright ⁷, ¹Brigham and Women's Hospital, Boston, MA, USA, Boston, MA, ²Organización Medica de Investigación, Buenos Aires, Argentina, Buenos Aires, Argentina, ³Cabrini Medical Centre, Monash University, Malvern, Australia, Malvern, Australia, ⁴Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ⁵University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁶AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁷New York University Langone Medical Center, New York, NY, USA, New York
Background/Purpose: Upadacitinib (UPA), an oral selective JAK1 inhibitor, has demonstrated favorable efficacy and acceptable safety in five Phase 3 global studies in patients with moderately…
Abstract Number: 815 • 2019 ACR/ARP Annual Meeting
Expression Profiling of Genes in Rheumatoid Fibroblast‑like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis
Koji Fukuda¹, Yasushi Miura ², Shinya Hayashi ¹, Toshihisa Maeda ³ and Ryosuke Kuroda ¹, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Division of Orthopedic Science, Department Of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Matsubara Mayflower Hospital, Kobe, Japan
Background/Purpose: Fas ligand (FasL) is a member of tumor necrosis factor superfamily (TNFSF6) and reported to contribute to synovial hyperplasia of rheumatoid arthritis (RA). Apoptosis…
Abstract Number: 925 • 2019 ACR/ARP Annual Meeting
Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database
Sebastian E. Sattui¹, Mangala Rajan ², Sarah Lieber ¹, Geyanne Lui ³, Jeffrey Curtis ⁴, Lisa Mandl ⁵ and Iris Navarro-Millan ², ¹Hospital for Special Surgery, New York, ²Weill Cornell Medicine, New York, ³Weill-Cornell Medicine, New York, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Inflammation has been thought to be a risk factor for cognitive impairment and dementia. RA, an autoimmune inflammatory disorder is associated with a high…
Abstract Number: 1132 • 2019 ACR/ARP Annual Meeting
Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
Deepan Dalal¹, Tingting Zhang ², Hiren Verma ³ and Theresa Shireman ², ¹Brown University, Riverside, RI, ²Brown University, Providence, RI, ³Brown University School of Public Health, Providence, RI
Background/Purpose: Biologic disease modifying agents (DMARDs) are an integral part of rheumatoid arthritis (RA) treatment, but the adoption of infusion-based products has not been reported.…
Abstract Number: 1334 • 2019 ACR/ARP Annual Meeting
Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Dalifer Freites Nuñez¹, Leticia León ², Marta Redondo ³, Cristina Vadillo Font ⁴, Pia Lois ⁵, Arkaitz Mucientes Ruiz ⁴, Luis Rodríguez-Rodríguez ⁶, Benjamín Fernández Gutiérrez ⁷, Juan Angel Jover Jover ⁴ and lydia Abasolo Alcazar ⁴, ¹Hospital Clínico San Carlos, MADRID, Spain, ²Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, ³Universidad Camilo José Ceja, Madrid, Madrid, Spain, ⁴HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Fundación para la Investigación Biomedica, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid
Background/Purpose: Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. The experience of fatigue…
Abstract Number: 1361 • 2019 ACR/ARP Annual Meeting
Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Jatin Mistry ¹, Margaret Sibley ², Catherine Smith ³, Malama Sumbwanyambe ² and Patrick Kiely², ¹St George's University of London, London, United Kingdom, ²St George's University Hospitals NHS Trust, London, United Kingdom, ³St Georges University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ACR/EULAR guidelines recommend remission or low DAS28 as the treat to target goal for patients with rheumatoid arthritis (RA). Alternative patient reported outcomes include…
Abstract Number: 1387 • 2019 ACR/ARP Annual Meeting
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partial Response to Adalimumab
Jeffrey Curtis¹, Daniel Aletaha ², Gerd Burmester ³, Kerri Ford ⁴, Hubert van Hoogstraten ⁵, Henry Leher ⁶, Karthinathan Thangavelu ⁷ and Vivian Bykerk ⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Medical University of Vienna, Vienna, Austria, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Sanofi Genzyme, Bridgewater, NJ, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁷Sanofi Genzyme, Boston, MA, ⁸Hospital for Special Surgery, New York City, NY
Background/Purpose: Guidelines recommend adjusting therapy in patients with RA who fail to reach low disease activity or remission. Partial responders to a TNF inhibitor may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].